Type 2 Diabetes (T2D) Clinical Trials

Find Type 2 Diabetes (T2D) Clinical Trials Near You

Foot Temperature and Diabetic Foot Ulcer Risk: Using the FeetSee Device to Generate a Unique Foot Temperature Dataset.

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

Diabetic foot ulcers (DFUs) are a major cause of morbidity, lower-extremity amputation and healthcare costs in people with diabetes. DFUs often develop without pain or warning symptoms because of diabetic peripheral neuropathy, so patients may not recognise early signs of tissue damage. Monitoring plantar foot skin temperature is a promising strategy to detect early hot-spots of inflammation that precede ulceration and could trigger timely preventive action. This prospective, single-group study will enrol adults with type 1 or type 2 diabetes, a history of plantar DFU that has been healed for at least 6 weeks, and evidence of diabetic peripheral neuropathy. Participants will be recruited from hospital clinics in the United Kingdom and Lithuania. After a baseline assessment (including medical history and neuropathy testing), each participant will receive the FeetSee system, consisting of a thermal camera attached to their own smartphone or tablet, a stand, and the FeetSee mobile application. Participants will be instructed to acquire thermal and optical images of both feet at home at least once per day for 6-9 months, or until a new DFU develops. Images will be uploaded securely to cloud storage, where the FeetSee algorithm will analyse temperature patterns, comparing mirrored regions of both feet to identify potential inflammatory hot-spots associated with DFU risk. Participants will continue to receive standard clinical care throughout the study. The primary objective is to generate a longitudinal foot temperature dataset in this high-risk population and use it to retrospectively test and refine the FeetSee algorithm for predicting DFU occurrence. The primary outcome is the incidence of new DFUs during follow-up. Secondary objectives are to assess the feasibility and acceptability of daily device use (recruitment, retention, adherence, user and healthcare-provider questionnaires) and to document any device-related or system-related safety issues.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Males/females aged over 18 years.

• Type 1 or type 2 diabetes.

• History of plantar diabetic foot ulcer(s).

• Foot ulcer healed for at least 6 weeks before entry into study, as determined by a specialist healthcare provider.

• Presence of diabetic peripheral neuropathy defined by either of the following:

‣ Inability to detect the monofilament (10g) applied at two foot sites, including the apex of the Hallux (ADA guidelines 2008 Diabetes Care 31(1)).

⁃ A Vibration Perception Threshold (VPT) \>20V, and/or by inability to detect application of the monofilament at the apex of the Hallux.

• Presence of at least one palpable foot pulse.

Locations
Other Locations
Lithuania
Vilnius University Hospital Santaros Klinikos
RECRUITING
Vilnius
United Kingdom
Blackpool Teaching Hospitals NHS Trust
NOT_YET_RECRUITING
Blackpool
Lancashire Teaching Hospitals NHS Foundation Trust
NOT_YET_RECRUITING
Lancaster
Manchester University NHS Foundation Trust (MFT)
RECRUITING
Manchester
Contact Information
Primary
Helena Grinberg Rashi, Phd
helena@diabetis.lt
+31615636666
Backup
Rytis Zajančkauskas, MD
rytis@diabetis.lt
Time Frame
Start Date: 2025-12-16
Estimated Completion Date: 2027-05-30
Participants
Target number of participants: 100
Treatments
FeetSee Foot Monitoring Cohort
Adults with type 1 or type 2 diabetes, peripheral neuropathy, and a recently healed plantar diabetic foot ulcer will use the FeetSee System at home in addition to their usual diabetic foot care. After baseline clinical assessment and training, participants will be asked to acquire at least one thermal (and accompanying optical) image of the plantar surface of both feet per day using the FeetSee thermal camera, stand, and smartphone/tablet application over the follow-up period (approximately 6-9 months) or until a new diabetic foot ulcer develops. Images are uploaded securely for later analysis of plantar temperature patterns. No experimental drug or change in standard clinical management is mandated by the protocol; the device is used for image collection only.
Related Therapeutic Areas
Sponsors
Collaborators: Vilnius University Hospital Santaros Klinikos, Manchester University NHS Foundation Trust, Horizon 2020 - European Commission, Lancashire Teaching Hospitals NHS Foundation Trust
Leads: Diabetis JSC

This content was sourced from clinicaltrials.gov